Transcriptional functionality of germ line p53 mutants influences cancer phenotype

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3789-3795

  Monti, Paola ^a   Ciribilli, Yari ^a   Jordan, Jennifer ^b   Menichini, Paola ^a   Umbach, David M ^b   Resnick, Michael A ^b   Luzzatto, Lucio ^c   Inga, Alberto ^a   Fronza, Gilberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ALLELE; ARTICLE; CANCER; CANCER PATIENT; CLINICAL FEATURE; CLINICAL STUDY; COMPARATIVE STUDY; CORRELATION FUNCTION; DATA BASE; FAMILY HISTORY; GENE MUTATION; GENETIC TRANSCRIPTION; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION RETRIEVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; CHILD; GENES, P53; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS; PHENOTYPE; PRECANCEROUS CONDITIONS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447128134     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2545     Document Type: Article

References (34)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331: 834-42.
3. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24: 2899-908.
4. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
5. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
6. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9.
7. Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10: 191-202.
8. Rowan S, Ludwig RL, Haupt Y, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996;15:827-38.
9. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996;16: 4952-60.
10. Monti P, Campomenosi P, Ciribilli Y, et al. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene 2002;21:1641-8.
11. Monti P, Campomenosi P, Ciribilli Y, et al. Characterization of the p53 mutants ability to inhibit p73 β transactivation using a yeast-based functional assay. Oncogene 2003;22:5252-60.
12. Campomenosi P, Monti P, Aprile A, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001;20:3573-9.
13. Inga A, Monti P, Fronza G, Darden T, Resnick MA. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 2001;20:501-13.
14. Inga A, Resnick MA. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 2001;20:3409-19.
15. Inga A, Storici F, Darden TA, Resnick MA. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002;22:8612-25.
16. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
17. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 2003;100:9934-9.
18. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
19. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643-50.
20. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
21. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60.
22. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
23. Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 2002;39:941-4.
24. Hoffman EB, Sen PK, Winberg CR. Within-cluster resampling. Biometrika 2001;88:1121-34.
25. Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 1998;16: 1369-72.
26. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 1998;16:2527-39.
27. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005;65: 2108-14.
28. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006; 27:14-20.
29. Brown BW, Costello TJ, Hwang SJ, Strong LC. Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome. Hum Genet 2005;118:489-98.
30. Tomso DJ, Inga A, Menendez D, et al. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A 2005;102:6431-6.
31. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
32. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci U S A 2006;103: 1406-11.
33. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531-3.
34. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004;36:63-8.